Tech Company Financing Transactions

Deciphera Pharmaceuticals Funding Round

Viking Global Investors, New Leaf Venture Partners and Redmile Group participated in a $52 million Series C venture round for Deciphera Pharmaceuticals. The funding round closed on 6/2/2017.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

200 Smith St.
Waltham, MA 02451
USA

Phone

(781) 209-6400

Website

www.deciphera.com

Email Address

[email protected]

Overview

Deciphera Pharmaceuticals (NASDAQ: DCPH) was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce best-in-class small molecule switch inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Steven Hoerter

        

Chief Financial Officer

Tucker Kelly

        

Chief Scientific Officer

Daniel Flynn

        

VP - General Counsel

Jeffrey Held

        

VP - Human Resources

Peter Lasky

        

Browse more venture capital transactions:

Prev: 6/2/2017: Evolve Vacation Rental Network venture capital transaction
Next: 6/2/2017: SpyCloud venture capital transaction

Share this article

About Our VC Transactions Data

Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary